22 Pharmaceutical MNC Leaders' Messages to the Two Sessions


With the successful conclusion of the national two sessions on May 28th, the government work report, the Suggestions of representatives and committee members as well as other hot issues during the two sessions have attracted extensive attention. Among them, expanding opening-up is undoubtedly a highlight of this year's NPC and CPPCC sessions. On the eve of the two sessions, the release of the landmark document "Opinions on Accelerating the Improvement of the Socialist Market Economy System in the New Era" marked a new step forward in the reform of the economic system and set the tone for the opening up of the two sessions. 

On May 22th, Premier LI Keqiang proposed in the government work report that "we should unswervingly open wider to the outside world, stabilize industrial and supply chains, and promote reform and development through opening up." We will open to the outside world at a higher level, stabilize the basic market for foreign trade and investment, and create a market environment in which domestic and foreign enterprises are treated as equals and compete on a level playing field. At the same time, the state will issue the 2020 edition of “the Industrial Catalogue for Encouraging Foreign Investment”, and continue to add more items of encouragement, with the focus on promoting high-quality development of the manufacturing sector.

In addition to opening to the outside world, another hot topic of this year's NPC and CPPCC should be health. The sudden outbreak of Covid-19 further highlights the importance of public health security and the value of healthy China strategy. As a key part of the global fighting against covid-19, the significance of pharmaceutical innovation has been strengthened in the topic of this year's two sessions.

Two sessions were finally held after the outbreak, at this special historical moment, the China leader of RDPAC 22 member companies have shared their views. They highly praised China's achievements in improving the business environment and accelerating the introduction of innovative drugs. They are also fully confidence in the strength and resilience of China's healthcare system, and are optimistic about the potential and future development of China's healthcare market. They will continue to increase presence in the Chinese market and look forward to working with all sectors of the industry to build a sustainable Chinese pharmaceutical innovation ecosystem. At the same time, they also issued the following appeals:

1. Further improve the business environment, strengthen IP protection, accelerate the improvement of the socialist market economy and create a fair market environment for competition
2. Promote the simultaneous development and marketing of innovative drugs at home and abroad, so that innovative drugs can benefit Chinese patients as soon as possible
3. Comprehensively evaluate the value of drug innovation, improve the value pricing mechanism, and encourage industrial innovation to face the challenges of diseases
4. Deepen the reform of the medical security system, build a diversified security system, realize the sustainable development of the medical insurance fund, and improve the accessibility and affordability of drugs for patients
5. Increase public health investment, improve the public health service system focusing on prevention, and attach importance to early prevention and chronic disease management
6. Promote technical exchanges and cooperation between domestic and foreign enterprises, maintain the momentum of opening up to the outside world, and better integrate into the global pharmaceutical innovation system


The following are the messages from the leaders of 22 RDPAC member companies in China (in alphabetical order of company names) :

1. Tony AU
General Manager, AbbVie China
AbbVie has achieved a milestone of its own——the completion of the transformative acquisition of Allergan. We have become a biopharmaceutical company with leadership positions in key therapeutic areas: Immunology, Hematologic Oncology, Neuroscience, and Allergan Aesthetics. This enables us to expand our partnership with stakeholders in China, with whom we look forward to advancing healthcare and better serving Chinese people in areas we have expertise in, such as Immunology, Oncology, Virology and Neuroscience.

The two most important political conferences are in session. We at the new AbbVie hope that China can keep its strong momentum of reform and opening-up, increasing support to the approval and access of innovative medicines for the well-being of the patients. We’re confident that China’s pharmaceutical industry will continue to grow driven by opening-up, innovation and collaboration. We are committed to being part of the efforts through working closely with the Chinese government.

2. My Linh Kha
VP &GM, Amgen China
China's Two Sessions 2020 has attracted domestic and worldwide attention. In particular, Premier Li Keqiang’s remark, following the delivery of the Government Work Report to the third session of the 13th National People's Congress on May 22, 2020, that “Life is invaluable!” resonate strongly. It’s a statement that aligns with the Chinese government’s aspiration to improve the health and well-being of all Chinese people. By 2030, China will step into a profoundly different society, one where more than 25% of the population will be over 60 years of age.  

As a global biotechnology leader, Amgen’s actions matches the Chinese government’s priorities through our own focus on healthy aging and the delivery of new medicines to improve the health and wellness of Chinese patients. We will continue to work with all stakeholders to accelerate the shift of healthcare from a “break and fix” model to a “Predict and Prevent” model, thus pushing forward the healthy aging agenda and fulfilling  the “Healthy China 2030” vision.

3. Leon Wang
Executive Vice President, International & China, AstraZeneca
AstraZeneca believes that an optimized market environment and a fair, positive and dynamic investment atmosphere can maximize an enterprise's initiative in innovation, help attract and pool domestic and foreign resources, and strengthen the competitiveness of local innovation. We look forward to the continuous improvement of the international business environment by the government. We will also vigorously support and promote cross-industry and cross-regional cooperation, and sincerely hope to deepen our level of innovation and maximize the investment returns of 1+1>2.

AstraZeneca is looking forward to seeing more government support in encouraging foreign pharmaceutical companies to develop new drugs in China, while continuing to speed up the assessment and approval of new drugs to better meet clinical needs and patient access to medicines. We hope that, in the future, the gap between the time needed for the listing of domestic and foreign new drugs will be further shortened, so that the drugs can be listed at the same time at home and abroad, and 1.1 new drugs can even be listed earlier than those in foreign markets.

AstraZeneca hopes the government will increase its support for the development of smart healthcare in the future, thus encouraging enterprises to explore the application of cutting-edge technologies including the Internet of things, artificial intelligence, big data, and 5G, with the healthcare industry. We envision that, through the whole patient journey, patients can benefit from the convenience brought by these innovative technologies, through which, at the same time, the ability of primary medical service can be improved to alleviate the problem of medical resource allocation as well. Meanwhile, AstraZeneca also hopes that the government can further improve the public health system, comprehensively enhance the capacity of health management and disease prevention, and promote the digitalization, intelligent transformation and upgrading of the medical and health industry, so that the "Internet Plus Healthcare" model, which plays an important role in the pandemic, can benefit the whole people as soon as possible.

4. Shirley Xu
GM of Greater China, Baxter
For 30 year, Baxter China has been committed to acting as a reliable partner of the Chinese government, healthcare providers and patients, with the motto of "in China, for China". We are glad to see the support provided by the government to further encourage foreign investments in innovation. As a highly localized multinational healthcare company, Baxter does and will continue to fully comply with national policies and continue to drive innovation to meet the needs of Chinese patients. We will also continue to innovate to introduce new products and business models, and act as a responsible corporate citizen, creating an all-win situation for patients, governments, and healthcare providers.

The Two Sessions once again emphasized the strategic value of One Healthy China. As a healthcare technology company with a diversified product portfolio including both prescription drugs and medical devices, owning the industrial chain from R & D, manufacturing, sales to service allows us to continue to provide advanced and professional products and services to Chinese patients and to a sustainable healthcare industry. During the COVID-19 outbreak, Baxter fully supported frontline medical facilities, leveraging the company’s advantages in renal and critical care, plus Internet+ to embrace digital healthcare. Chronically-ill patients were taken care of with innovative remote treatment management without taking up medical resources at the hospitals. In the future, we will further participate in the optimized allocation of medical resources, working with different stakeholders to increase healthcare accessibility and help more patients obtain high-quality medical products and services so as to fulfill our corporate mission of "saving and sustaining lives".

5. Wei Jiang
Executive Vice President and President of Bayer Pharmaceuticals Region China & APAC and President of Bayer Group Greater China
This year's "Two Sessions" sent a signal that the Chinese government has always put the economy, people's welfare and health first, which is very encouraging for Bayer, as a company deeply rooted in the country. With our vision of "Health For All, Hunger For None”, Bayer is firmly committed to continuous growth in China.

COVID-19 pandemic will accelerate the further development of China's public health system, and we expect to see more policies to advance medical innovation and collaboration. Bayer has a clear strategy in China, and we will leverage our expertise and advantage to speed up the introduction of innovative products, strengthening local innovation collaboration, actively supporting national policies and improving patient access to drugs for relieving their financial burden, thus contributing to the improvement of China's overall public health through close collaboration with all stakeholders.

China has become a global hotspot for medical innovation and a key enabler of innovation in future. The next decade will be the "golden age" for China's pharmaceutical industry. Bayer will seize this opportunity to engage into the development of China pharmaceutical industry and make greater efforts to support the "Healthy China 2030" strategy.

6. Felix Gutsche, 
President & CEO, Boehringer Ingelheim
China’s mainland, Hong Kong and Taiwan
The “Two Sessions” have sent out an important signal: China is effectively preventing and controlling the epidemic and the economy is recovering rapidly. Boehringer Ingelheim will continue to increase investment in China. We will join hands with all parties to foster innovation. In March this year, we just announced that the company will open its first overseas digital lab BI X in Shanghai. Our External Innovation Hub China will also be launched soon.

As the government work report delivered at the “Two Sessions” emphasized, all countries should work together to promote the establishment of a community of common destiny for all mankind to cope with public health crisis, severe economic recession and other global challenges. As a research-driven multinational pharmaceutical company, Boehringer Ingelheim will be committed to its mission and cooperate with global academic researchers, public institutions, international alliances and other biopharmaceutical companies, including those in China, in multiple projects as we jointly seek medical solutions to contain the pandemic. Meanwhile, we hope that China will offer more policy support to shore up pharmaceutical innovation and promote healthcare reform in a fair and sustainable manner during the fourteenth Five-Year plan. Boehringer Ingelheim aims to improve the health of Chinese people by innovation. We will fully support the “Healthy China 2030” Initiative. 

7. Yanhui Feng
Vice President, Eisai Co., Ltd
President, Eisai China Holdings Ltd. & Eisai China Inc.
As Prime Minister Keqiang Li stated in his work report, "at present, the epidemic has not been over yet, and the development task is extremely difficult. We must strive to minimize the losses caused by the epidemic and strive to complete goals and tasks of the economic and social development in this year." We believe that our industry will work together with all sectors of society to promote the construction of "Healthy China 2030". While orderly resuming work and production, we will pay more attention to "the life first", the challenges brought about by the aging of Chinese society and the unmet diverse medical needs.

Eisai China has always been taking root in China in the past 29 years and has been maintaining a beneficial, healthy and rapid growth. Eisai China adheres to the corporate philosophy of "hhc -human health care", and hopes that enterprises and the public will work together to provide patients with more innovative solutions and better medical and health services, and jointly contribute to the construction of "Healthy China 2030".

8. Julio Gay-Ger
President and General Manager, Lilly China
At the beginning of 2020, China and countries all over the world are facing the severe global public health emergencies of Coronavirus. The Chinese government's efficient and timely prevention and control of this epidemic and the mobilization of resources have attracted worldwide attention, and have achieved outstanding achievements in epidemic prevention and control.

In the post-epidemic era, as for how can China actively promote socioeconomic recovery and development under the normalization of this epidemic situation, ensure the well-being of the people, fulfill the responsibilities as a major country, and achieve the great goal of alleviating poverty and completing the tasks of building a moderately prosperous society in all respects on schedule, I believe that NPC deputies and CPPCC members will give a groundbreaking "China plan".

During the two sessions, the improvement and strengthening of the healthcare system and public health system would be a hot topic among NPC deputies and CPPCC members. We look forward to and recommend that under the guidance of the "Healthy China 2030" initiative:

1) The government further optimizes the international business environment, strengthens the protection of intellectual property rights, and vigorously promotes innovative research and development in the pharmaceutical sector by promoting technological exchanges and cooperation between domestic and foreign enterprises.

2) The government continuously strengthens the construction of public health and even the entire healthcare service system, and further improves the accessibility of innovative medicines, especially that in the primary-level healthcare services, so that efficient and convenient products can better benefit patients with major diseases such as diabetes and cancer.

9. Cecilia Qi
General Manager for Pharma and Vaccines, GSK China 
The coronavirus has closely linked the destiny of all humanity, and vaccines are the most effective methods of preventing and controlling infectious diseases. We hope public awareness to vaccines can keep up with the times. Full life-cycle coverage of vaccines helps to reduce the burden of disease on people of all ages and can also help to improve public health systems.

As a participant of pharmaceutical and healthcare industry, as well as the witness and beneficiary of the continuous improvement of the medical security system, GSK has been actively responding and supporting on healthcare reform and relevant policies, while bringing more innovative products to China to benefit more patients, and as a result, continuously improve the accessibility and affordability of the medicines. We believe that with the joint efforts, we can increase the public awareness to the full life-cycle vaccination, truly transforms the value of vaccine to the value of life, accelerate the implementation of “Health China 2030” initiative.

10. Alan Chen
General Manager, Ipsen China
"Health" is still a hot topic in China National Two Sessions. A sudden outbreak of Covid-19 caused people pay more attention to the importance of public health and safety which also provided an opportunity for accelerating the transformation of China medical industry. Due to the rapid development of Internet+ healthcare model, the corresponding medical policy will be upgraded accordingly, which will bring more convenience to patients.

Ipsen focuses on accelerating the innovation of new drugs, and has always been committed to improving the life quality of patients by new treatment and solutions, improving disease awareness, building academic communication platforms and promoting drug accessibility. Since being rooted in China for 28 years, meeting the needs of patients is the core of our strategic development. Ipsen has actively contributed in the fields of cancer, rare diseases, gastrointestinal and so on.

In recent years, Ipsen has accelerated the introduction of innovative rare disease medicines to China, striving to provide innovative treatment solutions for patients, adhering to the principle of patient centricity, and further improving the accessibility of medicines. For the payment problems of patients with rare diseases, the government needs to give priority to explore the ways of multi-funding and learn the successful experiences from other countries in order to reduce the economic and mental pressure of patients.

In the future, we look forward to working with all parties in China to continuously optimize the pharmaceutical innovation. We expect to obtain more policy support from government for the translational medicine, to promote drug accessibility and the realization of "Healthy China 2030".

11. Lorena Di Carlo
General Manager, Lundbeck China
As stated in the Healthy China 2030, we need to improve the capabilities in the prevention of mental crisis when incidents happen. We are grateful that we have been able to continue to deliver our medicines to meet rising needs of patients facing mental health challenges, exacerbated by the pandemic. We’ve also offered series of online mental health education programs in response to the call of the government. 

In the era of “post COVID-19”, we hereby advocate that government, enterprises, academia, experts, etc. to work together to enhance the incident mental health management capabilities. This includes the psychological trauma restoration and counselling for the patients, victims’ families and front-line healthcare workers, as well as the mental health education and advocacy for the public. Meanwhile, we sincerely advocate government to introduce innovative treatment for patients with depression, which could comprehensively control their emotional, cognitive, and physical symptoms. The significant improvement on patients’ cognition is critical for patient to restore their social function.

12. Rogier Janssens
Managing Director and General Manager of Merck‘s Biopharma business China 
During the COVID-19 pandemic, Merck makes every endeavor to ensure the stable supply of our products by continuously following the medicine demands from patients with chronic diseases. We have been cooperating with qualified and credible local health service platforms to help patients realize one-stop services including real-time online prescription, online consultation, diagnosis and treatment, and drug delivery. Besides active cooperation with the government in response to the pandemic, we also see the public’s pressing demands for quality medicines and innovative solutions. It will catalyze the construction of a new patient-centered public health landscape. Additionally, the resilience presented by the Chinese economy, the huge potential in China’s medical markets and the improving business environment all firmed our confidence to continuing our development in China. Entering a new normal post-pandemic phase, we expect to continue our good and close communications with governmental sectors and address patients’ needs in a cost-effective and affordable way with a prospect to better benefiting all the Chinese patients through high quality and innovative treatments. 

13. Joseph Romanelli
Senior Vice President of MSD and President of MSD in China
As we have seen over the past few months, investing into healthcare is critical for all countries. The 2020 Work Report demonstrates the Chinese government’s strong intentions to increase expenditures into public health, R&D, and basic medical services. With this focus, combined with the efforts of the bio-pharmaceutical sector, we can continue our work toward achieving the goals of healthcare reform and “Healthy China 2030”. In my role as President of MSD China, one of the premier scientific bio-pharmaceutical company in the world, we plan to support the efforts by introducing more innovative vaccines and therapeutics into China.

14. Xudong, Yin,
President of Novartis Pharmaceuticals APMA Region (Asia Pacific, Middle East and Africa) and President of Novartis Group (China)
The outbreak of COVID-19 has heightened the extreme importance of public health system. As a result, how to enhance such a system became a trendy topic during the “Two Sessions” this year. While China is expected to continue expanding the public health infrastructure, we hope the nation will beef up efforts in improving legislations and regulatory framework in a bid to tackle the root of public health challenge. The same is true with the disease management. Early prevention and early treatment of major types of diseases not only helps alleviate the pains for the patients, lower their economic burdens, but also produces significant savings for the whole nation, ultimately contributing to its economic development.

The COVID-19 outbreak has also further enhanced the awareness of the importance of innovations in the medicines sector. We hope the country can step up efforts in improving and effectively implementing the related laws and regulations regarding regulatory data protection. Such protection of innovative drugs in compliance in compliance with current laws and regulations, can help boost the IPRs protection in the medicines sector, drive innovation and transformation of this critical industry. In addition, we would suggest the country streamline the management and approval process for the human generic resources and release the detailed registration process related with clinical trials as soon as possible, in a bid to speed up the introduction of innovative medicines to China and ultimately benefits the patients.

Moreover, “Internet+Healthcare” has played a critical role in ensuring the access to medicines and medical services, enabling online diagnosis and health insurance payments during the COVID-19 outbreak. We expect the nation will leverage this opportunity to further increase the penetration of the Internet Plus Initiative in the medicines and healthcare sectors, to address the imbalanced allocation of medical resources in the country, generate great economic savings and facilitate the endeavor of achieving the goals outlined in the “Healthy China 2030” blueprint.

15. Christine ZHOU
Senior Vice President & President of Region China, Novo Nordisk 
Novo Nordisk will proactively seize opportunities brought by the accelerated process of new drug review and approval in China to introduce more innovative medicines into the Chinese market and improve the accessibility, so as to benefit more and more Chinese patients. Meanwhile, we aim to achieve simultaneous drug approval in China and globally, so that patients in China can benefit from our innovative medicines together with these in other countries.

2020 is the first checkpoint of three steps of strategic goals for “Healthy China 2030”. We will work closely with partners to accelerate digital innovation and continue to fulfill our commitment to change diabetes and other serious chronic diseases in China through building the ecosystem of ‘changing diabetes’, helping achieve the targets of the "Healthy China 2030". We hope that we could turn the battle we fight together against COVID-19 outbreak into an opportunity for China and the rest of the world. Congratulations on the successful conclusion of ‘Two Sessions’!

16. Wu Kun 
China Chief operating officer, Pfizer Biopharmaceutical Group
Premier Li Keqiang pointed out in the Report on the Work of the Government during the Third Session of the 13th National People’s Congress that it is necessary to increase investment in the R&D of vaccines, drugs and rapid detection technologies; it is also necessary to improve the level of basic medical services and increase efforts to ensure the basic livelihood. Around these key areas, Feng Danlong, member of the National Committee of the CPPCC and Corporate Affairs Senior Consultant of Pfizer China, submitted two proposals: Proposal on Promoting the Vaccination of the Aging Population to Improve Overall Health and Proposal on Promoting the Orderly Development of Commercial Health Insurance and Playing Its Supplementary Part in Basic Medical Insurance As Soon As Possible this year. She suggested that we should carry out the vaccination of the aging population to improve the overall vaccination rate, so as to pay attention to the details for disease prevention and control in advance and reduce the use of medical resources accordingly. This would support the realization of promoting the health of the aging population and the implementation of the strategic goal of a Healthier China. She also suggested that we should guide the development of commercial insurance in a standardized way, and focus on the deepening the orderly connection between basic medical insurance system and various supplementary guarantees including commercial insurance, so as to push the formation of orderly complementarity between commercial insurance and basic medical insurance as soon as possible.

As instructed by President Xi, we need to normalize the prevention and control of the pandemic in the long run, striving to seek opportunities in crisis and start a new chapter in a changing situation. Looking into 2020 and beyond, Pfizer will work together with the government and all parties in the industry as always to actively explore innovative and efficient solutions in terms of R&D of innovative drugs, disease prevention and control and lifecycle management of diseases. We are committed to bringing breakthroughs that change patients’ lives.

17. Hong Chow 
President, Roche China
In China, more than 10,000 people are diagnosed with cancer, and over 6,000 people die from cancer every day. This means, on average, 7 people are diagnosed and almost 5 people die every minute. The incidence and mortality of cancer in China are both the highest in the world. Cancer and other critical diseases severely threaten people’s health and quality of life and bring a significant economic burden to patients’ families and society. Experience at home and abroad has proved that early screening, early diagnosis and early treatment are the most effective measures against cancer. The earlier the discovery and intervention, the better the effect of lowering mortality and medical costs. Take Shanghai as an example. In 2013, the city launched a major public health service project to conduct colorectal cancer screening for community residents. The 5-year survival rate of cancer patients identified through screening was 24 percentage points higher than that of patients who did not participate in screening in the same year.

I propose that public health spending in the future should gradually expand its scope to cover early screenings of high-incidence cancers, such as lung cancer and breast cancer, in the light of study on incidence and susceptible population of different cancer types. In this way, we can shift from passive treatment to proactive prevention, reduce the overall cost of the society from its source, and improve the health condition of the entire population.

18. Pius S. Hornstein
General Manager General Medicines and Country Lead, Sanofi China
As one of the first healthcare multinationals to open offices in China, Sanofi is fully aligned with the national “Healthy China 2030” agenda, supporting the Chinese government’s five healthcare priorities and focusing on the prevention and control of five major diseases, and will accelerate the research and introduction of new products. Based on the Healthy China 2030 strategy, we’d like to make the following recommendations: 

1) Increase significantly the investment into health, chronic disease management and prevention especially for cardio-metabolic disease, gradually approaching the investment level of other countries with similar strong level of development, increasing the healthcare investment share in GDP;
2) Improve the vaccination rate of the entire population and provide the public health services emphasizing prevention;
3) Improve healthcare system for rare disease patients. By improving affordability via reimbursement, we hope more rare disease patients can get treatment and won’t fall into or fall back to poverty due to illness;
4) We expect to further enhance the access to innovative products/solutions, perfect value appraisal system and protect IP in the process of making policies.

19. Stephane MASCARAU
General Manager, Servier China
We believe that the overall goal of the development of China's pharmaceutical industry is to ensure patient access to high-quality, innovative medicines.

We are looking forward to speed up regulations for high quality and innovation products, such as on April 30, 2020, CDE issued the <Clinical technical requirements for drugs that have been listed overseas and not listed in China (draft for comments)>. The regulations are going in such direction to boost access to innovation to Chinese patients. 

Our long concern is how to ensure and follow quality for patients of drugs with such limitation of price (VBP).

The new patient flow from big hospitals to CHC, at the level of community health service centers and primary hospitals, standardized management should be further strengthened to improve the level of diagnosis and treatment. Diabetes, hypertension, angina and heart failure related medical trainings should be provided to general practitioners to optimize the diagnosis and treatment.

At the level of Internet hospitals and retail pharmacies, we are happy to see some provinces and cities begin to pilot the coverage of medical insurance. It is hoped that with the advancement of Internet + medical care, the process of medical insurance coverage can also be promoted synchronously and quickly, so as to facilitate more patients to get high-quality drug treatment in a more flexible way.

20. Sean Shan 
President, Takeda China
There are many uncertainties with the global economy due to the COVID-19 pandemic. The Chinese government has stated to further deepen its opening-up policy according to this year's Government Work Report. China is still the most important market in the world, and will remain so in a long term. Innovation is emphasized as a cornerstone of China’s sustainable development, particularly in health care sector. With such national policy, we’ve seen more innovative medicines and breakthrough therapies are introduced to China to benefit Chinese patients. Innovation will become the key driver for health care sector and will be the core factor for the success of the country. The promising future is encouraged for values-based, innovation-driven companies as Takeda to have a sustainable development in China.

We have set our pace in China to accelerate the journey from new drug development, manufacturing site to commercialization with focus on therapeutic areas including oncology, rare diseases, Gastroenterology (GI), and PDT products. Takeda will keep investing in China in the next five years to bring more innovative medicines more faster to China, ultimately help to realize “Healthy China “ initiative providing better health and brighter future for Chinese people.

21. Wu Xin
Managing Director, UCB China
The evolving COVID-19 pandemic is profoundly impacting our lives. More than ever we need radical collaboration to connect healthcare and improve chronic disease management to bring effective solutions to right patients as many as possible in a more timely manner.

22. Asgar Rangoonwala 
President, Xian Janssen Pharmaceutical Ltd.
The Healthy China 2030 Outline reveals a profound impact on the improvement of the health of Chinese people and the development of China's healthcare industry. As a multinational pharmaceutical company driven by innovation, we are honored to be able to fulfill our commitments and make contributions to promoting and realizing this strategic plan.

2020 marks the 35th anniversary of Xian Janssen in China, which underscores the importance of the Chinese market in Johnson & Johnson’s global strategy. We are filled with confidence in China, highly optimistic about the potential and future of China's healthcare market, and we have faith in both high-quality and high-speed development driven by innovation in China in the long run. In future, Xian Janssen will continue to invest more into the Chinese market, bring world-class innovative drugs to Chinese patients, cooperate with all fields to improve the accessibility, and enhance the life quality of patients, so as to create a future where disease is a thing of the past with joint efforts.

"The global outbreak of covid-19 has caused enormous human, economic and social damage”, said KANG Wei, Managing Director of RDPAC, “RDPAC and its member companies are actively researching and developing drugs and vaccines, and strengthening cooperation with countries and all sectors of society to jointly cope with the unprecedented crisis of mankind. At the same time, we remain committed to improving the access of all patients to innovative drugs, so that Chinese patients can enjoy the fruits of the world's medical innovation as soon as possible, so as to alleviate the suffering of patients, save lives and improve the quality of life."

Asgar Rangoonwala, Chairman of RDPAC Executive Committee and President of Xian Janssen Pharmaceutical Ltd., said that with the concept of "Healthy China through Innovation", RDPAC member companies have been an important force in promoting the development of China's pharmaceutical industry and the improvement of the pharmaceutical innovation ecosystem.

Related articles: